GlassScriptPhysician profile
Amy K Harris
NPI 1124034541
$9,051.33
in general payments reported to CMS, 2019-2025
56 companies · $2,599 in 2025
The $2,599 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.91 · 2022: $1,843 · 2023: $2,190 · 2024: $2,405 · 2025: $2,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,869 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,868.87 |
| Education | $324.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $613.20 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $605.77 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $554.25 | 2022-2025 | Opdivo, Augtyro, Opdualag |
| Daiichi Sankyo INC. | $435.96 | 2022-2025 | Enhertu, Injectafer |
| Lilly USA, LLC | $418.98 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Janssen Biotech, INC. | $392.59 | 2022-2025 | Rybrevant, Darzalex, Tecvayli |
| Gilead Sciences, INC. | $360.05 | 2022-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $358.38 | 2022-2025 | Jemperli, Zejula |
| Seagen INC. | $339.97 | 2021-2023 | Tukysa, Adcetris, Padcev |
| Takeda Pharmaceuticals U.S.A., INC. | $316.43 | 2022-2025 | Ninlaro, Iclusig |
| Abbvie INC. | $313.59 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $293.27 | 2023-2025 | Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $291.31 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Rigel Pharmaceuticals, INC. | $243.95 | 2022-2025 | Rezlidhia, Tavalisse, Gavreto |
| Amgen INC. | $239.67 | 2022-2023 | Lumakras |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $237.45 | 2022-2025 | Phesgo, Perjeta, Tecentriq |
| Celgene Corporation | $234.34 | 2022-2024 | Pomalyst, Reblozyl, Opdualag |
| Incyte Corporation | $230.76 | 2022-2025 | Monjuvi, Pemazyre, Jakafi |
| Astellas Pharma US INC | $226.18 | 2022-2025 | Padcev, Xtandi |
| Genzyme Corporation | $203.23 | 2022-2025 | |
| Puma Biotechnology, INC. | $195.14 | 2023-2025 | |
| Eisai INC. | $172.13 | 2022-2025 | |
| Morphosys, US INC. | $155.86 | 2022-2023 | Monjuvi |
| Regeneron Healthcare Solutions, INC. | $150.14 | 2023-2025 | Libtayo |
| Emd Serono, INC. | $127.33 | 2022-2025 | Bavencio, Tepmetko |
| Tempus Ai, INC | $116.15 | 2024-2025 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $95.91 | 2023-2025 | Fotivda |
| Beigene USA, INC. | $92.83 | 2023-2024 | Brukinsa |
| Bayer Healthcare Pharmaceuticals INC. | $91.51 | 2022-2025 | |
| Servier Pharmaceuticals LLC | $90.79 | 2022-2025 | |
| Exelixis INC. | $71.13 | 2024-2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $60.97 | 2025 | |
| Stemline Therapeutics INC. | $59.85 | 2023-2025 | Orserdu |
| Taiho Oncology, INC. | $58.49 | 2022-2025 | |
| Sobi, INC | $40.36 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $39.81 | 2022-2025 | Ultomiris |
| Genmab U.S., INC. | $39.73 | 2023-2024 | Epkinly |
| Array Biopharma INC | $38.85 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Tersera Therapeutics LLC | $38.34 | 2024-2025 | Zoladex |
| Pharmacosmos Therapeutics INC. | $36.84 | 2025 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $34.64 | 2022 | |
| Legend Biotech USA INC. | $32.39 | 2025 | Carvykti |
| Blueprint Medicines Corporation | $28.99 | 2022-2023 | Ayvakit |
| Myriad Genetic Laboratories, INC. | $28.49 | 2022-2025 | Myrisk |
| Novocure INC. | $28.05 | 2025 | Optune Lua (Novottf-200t) |
| Azurity Pharmaceuticals, INC. | $26.25 | 2025 | Danziten |
| Beone Medicines USA, INC. | $25.81 | 2025 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $25.71 | 2024 | |
| Pharmaessentia USA Corporation | $22.82 | 2025 | Besremi |
| Fennec Pharmaceuticals, INC. | $19.29 | 2025 | Fyarro |
| Apellis Pharmaceuticals, INC. | $18.10 | 2023 | Empaveli |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.52 | 2024 | |
| Foundation Medicine, INC. | $16.77 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $16.58 | 2025 | Onivyde |
| Karyopharm Therapeutics INC. | $16.38 | 2024 | Xpovio |
| Kyowa Kirin, INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.